April 14, 2026

OpenAI and Novo partnership for AI-driven obesity drug development

OpenAI to Accelerate Obesity Drug Development as it Partners with Novo

Novo Nordisk, the Danish pharmaceutical giant has struck a partnership with OpenAI to integrate artificial intelligence across its entire business,  As the race to dominate the growing weight-loss drug market...
Read More